Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 2 2Phase NA 1Phase 1/2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Pancreatic Neoplasms 18Carcinoma, Non-Small-Cell Lung 5Urinary Bladder Neoplasms 3Nasopharyngeal Carcinoma 3Recurrence 2Non-Muscle Invasive Bladder Neoplasms 2Lung Neoplasms 2Carcinoma, Hepatocellular 2Biliary Tract Neoplasms 2Uterine Neoplasms 1Thromboembolism 1Stomach Neoplasms 1Ovarian Neoplasms 1Osteosarcoma 1Neoplasm Metastasis 1Nasopharyngeal Neoplasms 1NSCLC 1Malnutrition 1Lymphoma, T-Cell, Peripheral 1Lymphoma, T-Cell 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma, Extranodal NK-T-Cell 1Locally Advanced Pancreatic Cancer 1Infiltrating Bladder Urothelial Carcinoma 1Immunoblastic Lymphadenopathy 1Hypoxia 1Gallbladder Neoplasms 1Cholangiocarcinoma 1

Interventions

Electroporation 2Radiosurgery 1Heavy Ion Radiotherapy 1Gemcitabine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase NA × Locally Advanced Pancreatic Cancer × Gemcitabine × Clear all
NCT06494514 2024-07-10

NALIRIFOX Combined With PD-1 Sequential Radiotherapy Versus AG Combined With PD-1 Sequential Radiotherapy as First-line Treatment of Locally Advanced Pancreatic Cancer

The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School

Phase NA Recruiting
40 enrolled
Gastrointestinal

Locally Advanced Pancreatic Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡